Abstract Details

Title Correlation of Cognitive Impairment with Aß42/40 Peripheral Blood Biomarker

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P10 - Poster Session 10 (8:00 AM-9:00 AM)

Poster/Presentation
Number 12-003

Objective Correlation of peripheral blood plasma Aβ 42/40 ratios with cognitive function decline and dementia risk, serving as a biomarker indicator of the effect of glymphatic dysfunction on dementia.

Background The glymphatic system clears neurotoxic proteins, including amyloid beta 42 (Aβ42) via CSF clearance during sleep. Reduced plasma Aβ42/40 ratios are associated with impaired clearance and increased dementia risk, often outperforming Aβ42 alone. Establishing its predictive role in real-world cohorts will aid early detection of neurodegeneration with simple cognitive screening test in clinic.

Design/Methods

Retrospective cohort of 44 patients (≥50 years) with plasma Aβ42/40 values and Montreal cognitive assessment test (MoCA) score on follow-up. Cognitive functional impairment with age and APOE genotype was correlated. FDA approved serum Aβ42/40 ratios with low risk >0.17 and intermediate risk <0.17 - 0.16 and high risk < 0.15 level was considered as biomarker for Alzheimer's disease.

Results A significant positive association was observed between β-Amyloid 42/40 ratio and total MoCA score
(β = 65.78, SE = 29.25, p = 0.03, R² = 0.12).
For every 0.01-unit increase in amyloid ratio, MoCA score increased by approximately 0.66 points.
Participants with higher amyloid ratios (> 0.17–0.18) generally scored above the normal cognition score threshold (MoCA ≥ 26), whereas those with lower ratios (< 0.16–0.15) commonly had MoCA scores < 26, indicating mild cognitive impairment.

Conclusions A simple Montreal cognitive assessment is clinical tool indirectly indicate that lower β-Amyloid 42/40 ratios—reflecting greater amyloid accumulation—are associated with poorer cognitive performance (MoCA < 26). Awareness of Montreal Cognitive Assessment has linear relationship with ABeta42/20 ratio in absence of the clinical laboratory test availability. Physician may able to educate patients with confidence that the low MoCA test score is indicator of increased risk of Alzheimer's disease. Small sample size is limitation of the study, we are further analyzing data to report in future.

Authors/Disclosures
Maya Salimath, Undergrad PRESENTER	Miss Salimath has received personal compensation for serving as an employee of Quartino Chicago.
Suresh Kumar, MD (Neurology & Headache Center)	Dr. Kumar has nothing to disclose.
Hrishikesh Ambekar	Mr. Ambekar has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Investigative Research Bureau. Mr. Ambekar has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Investigative Research Bureau. Mr. Ambekar has received research support from Young Scientists of America . Mr. Ambekar has a non-compensated relationship as a Student with Young Scientists of America that is relevant to AAN interests or activities.
Mahith Ravulapati	Mr. Ravulapati has nothing to disclose.
Anbu M. Subramanian	Mr. Subramanian has nothing to disclose.
Vasishta Yedlapally	Mr. Yedlapally has nothing to disclose.

��ɫ��

��ɫ��